Mixed cationic liposomes for brain delivery of drugs by the intranasal route: The acetylcholinesterase reactivator 2-PAM as encapsulated drug model

Tatiana N. Pashirova, Irina V. Zueva, Konstantin A. Petrov, Svetlana S. Lukashenko, Irek R. Nizameev, Natalya V. Kulik, Aleksandra D. Voloshina, L. Almásy, Marsil K. Kadirov, Patrick Masson, Eliana B. Souto, Lucia Ya Zakharova, Oleg G. Sinyashin

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

New mixed cationic liposomes based on L-α-phosphatidylcholine and dihexadecylmethylhydroxyethylammonium bromide (DHDHAB) were designed to overcome the BBB crossing by using the intranasal route. Synthesis and self-assembly of DHDHAB were performed. A low critical association concentration (0.01 mM), good solubilization properties toward hydrophobic dye Orange OT and antimicrobial activity against gram-positive bacteria Staphylococcus aureus (MIC=7.8 μg mL–1) and Bacillus cereus (MIC=7.8 μg mL–1), low hemolytic activities against human red blood cells (less than 10%) were achieved. Conditions for preparation of cationic vesicles and mixed liposomes with excellent colloidal stability at room temperature were determined. The intranasal administration of rhodamine B-loaded cationic liposomes was shown to increase bioavailability into the brain in comparison to the intravenous injection. The cholinesterase reactivator, 2-PAM, was used as model drug for the loading in cationic liposomes. 2-PAM-loaded cationic liposomes displayed high encapsulation efficiency (∼ 90%) and hydrodynamic diameter close to 100 nm. Intranasally administered 2-PAM-loaded cationic liposomes were effective against paraoxon-induced acetylcholinesterase inhibition in the brain. 2-PAM−loaded liposomes reactivated 12 ± 1% of brain acetylcholinesterase. This promising result opens the possibility to use marketed positively charged oximes in medical countermeasures against organophosphorus poisoning for reactivation of central acetylcholinesterase by implementing a non-invasive approach, via the “nose-brain” pathway.

Original languageEnglish
Pages (from-to)358-367
Number of pages10
JournalColloids and Surfaces B: Biointerfaces
Volume171
DOIs
Publication statusPublished - Nov 1 2018

Fingerprint

pulse amplitude modulation
Pulse amplitude modulation
Liposomes
Acetylcholinesterase
brain
Brain
delivery
drugs
routes
Pharmaceutical Preparations
bromides
cholinesterase
rhodamine B
bioavailability
countermeasures
staphylococcus
Bacillus
Phosphatidylcholines
Bromides
poisoning

Keywords

  • Acetylcholinesterase
  • Cationic liposomes
  • Drug delivery systems
  • Organophosphorus agent
  • Paraoxon
  • Pralidoxime chloride
  • Self-assembly
  • Surfactant

ASJC Scopus subject areas

  • Biotechnology
  • Surfaces and Interfaces
  • Physical and Theoretical Chemistry
  • Colloid and Surface Chemistry

Cite this

Mixed cationic liposomes for brain delivery of drugs by the intranasal route : The acetylcholinesterase reactivator 2-PAM as encapsulated drug model. / Pashirova, Tatiana N.; Zueva, Irina V.; Petrov, Konstantin A.; Lukashenko, Svetlana S.; Nizameev, Irek R.; Kulik, Natalya V.; Voloshina, Aleksandra D.; Almásy, L.; Kadirov, Marsil K.; Masson, Patrick; Souto, Eliana B.; Zakharova, Lucia Ya; Sinyashin, Oleg G.

In: Colloids and Surfaces B: Biointerfaces, Vol. 171, 01.11.2018, p. 358-367.

Research output: Contribution to journalArticle

Pashirova, TN, Zueva, IV, Petrov, KA, Lukashenko, SS, Nizameev, IR, Kulik, NV, Voloshina, AD, Almásy, L, Kadirov, MK, Masson, P, Souto, EB, Zakharova, LY & Sinyashin, OG 2018, 'Mixed cationic liposomes for brain delivery of drugs by the intranasal route: The acetylcholinesterase reactivator 2-PAM as encapsulated drug model', Colloids and Surfaces B: Biointerfaces, vol. 171, pp. 358-367. https://doi.org/10.1016/j.colsurfb.2018.07.049
Pashirova, Tatiana N. ; Zueva, Irina V. ; Petrov, Konstantin A. ; Lukashenko, Svetlana S. ; Nizameev, Irek R. ; Kulik, Natalya V. ; Voloshina, Aleksandra D. ; Almásy, L. ; Kadirov, Marsil K. ; Masson, Patrick ; Souto, Eliana B. ; Zakharova, Lucia Ya ; Sinyashin, Oleg G. / Mixed cationic liposomes for brain delivery of drugs by the intranasal route : The acetylcholinesterase reactivator 2-PAM as encapsulated drug model. In: Colloids and Surfaces B: Biointerfaces. 2018 ; Vol. 171. pp. 358-367.
@article{6b5b12035d4f4b13affd5a50c567f7a9,
title = "Mixed cationic liposomes for brain delivery of drugs by the intranasal route: The acetylcholinesterase reactivator 2-PAM as encapsulated drug model",
abstract = "New mixed cationic liposomes based on L-α-phosphatidylcholine and dihexadecylmethylhydroxyethylammonium bromide (DHDHAB) were designed to overcome the BBB crossing by using the intranasal route. Synthesis and self-assembly of DHDHAB were performed. A low critical association concentration (0.01 mM), good solubilization properties toward hydrophobic dye Orange OT and antimicrobial activity against gram-positive bacteria Staphylococcus aureus (MIC=7.8 μg mL–1) and Bacillus cereus (MIC=7.8 μg mL–1), low hemolytic activities against human red blood cells (less than 10{\%}) were achieved. Conditions for preparation of cationic vesicles and mixed liposomes with excellent colloidal stability at room temperature were determined. The intranasal administration of rhodamine B-loaded cationic liposomes was shown to increase bioavailability into the brain in comparison to the intravenous injection. The cholinesterase reactivator, 2-PAM, was used as model drug for the loading in cationic liposomes. 2-PAM-loaded cationic liposomes displayed high encapsulation efficiency (∼ 90{\%}) and hydrodynamic diameter close to 100 nm. Intranasally administered 2-PAM-loaded cationic liposomes were effective against paraoxon-induced acetylcholinesterase inhibition in the brain. 2-PAM−loaded liposomes reactivated 12 ± 1{\%} of brain acetylcholinesterase. This promising result opens the possibility to use marketed positively charged oximes in medical countermeasures against organophosphorus poisoning for reactivation of central acetylcholinesterase by implementing a non-invasive approach, via the “nose-brain” pathway.",
keywords = "Acetylcholinesterase, Cationic liposomes, Drug delivery systems, Organophosphorus agent, Paraoxon, Pralidoxime chloride, Self-assembly, Surfactant",
author = "Pashirova, {Tatiana N.} and Zueva, {Irina V.} and Petrov, {Konstantin A.} and Lukashenko, {Svetlana S.} and Nizameev, {Irek R.} and Kulik, {Natalya V.} and Voloshina, {Aleksandra D.} and L. Alm{\'a}sy and Kadirov, {Marsil K.} and Patrick Masson and Souto, {Eliana B.} and Zakharova, {Lucia Ya} and Sinyashin, {Oleg G.}",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.colsurfb.2018.07.049",
language = "English",
volume = "171",
pages = "358--367",
journal = "Colloids and Surfaces B: Biointerfaces",
issn = "0927-7765",
publisher = "Elsevier",

}

TY - JOUR

T1 - Mixed cationic liposomes for brain delivery of drugs by the intranasal route

T2 - The acetylcholinesterase reactivator 2-PAM as encapsulated drug model

AU - Pashirova, Tatiana N.

AU - Zueva, Irina V.

AU - Petrov, Konstantin A.

AU - Lukashenko, Svetlana S.

AU - Nizameev, Irek R.

AU - Kulik, Natalya V.

AU - Voloshina, Aleksandra D.

AU - Almásy, L.

AU - Kadirov, Marsil K.

AU - Masson, Patrick

AU - Souto, Eliana B.

AU - Zakharova, Lucia Ya

AU - Sinyashin, Oleg G.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - New mixed cationic liposomes based on L-α-phosphatidylcholine and dihexadecylmethylhydroxyethylammonium bromide (DHDHAB) were designed to overcome the BBB crossing by using the intranasal route. Synthesis and self-assembly of DHDHAB were performed. A low critical association concentration (0.01 mM), good solubilization properties toward hydrophobic dye Orange OT and antimicrobial activity against gram-positive bacteria Staphylococcus aureus (MIC=7.8 μg mL–1) and Bacillus cereus (MIC=7.8 μg mL–1), low hemolytic activities against human red blood cells (less than 10%) were achieved. Conditions for preparation of cationic vesicles and mixed liposomes with excellent colloidal stability at room temperature were determined. The intranasal administration of rhodamine B-loaded cationic liposomes was shown to increase bioavailability into the brain in comparison to the intravenous injection. The cholinesterase reactivator, 2-PAM, was used as model drug for the loading in cationic liposomes. 2-PAM-loaded cationic liposomes displayed high encapsulation efficiency (∼ 90%) and hydrodynamic diameter close to 100 nm. Intranasally administered 2-PAM-loaded cationic liposomes were effective against paraoxon-induced acetylcholinesterase inhibition in the brain. 2-PAM−loaded liposomes reactivated 12 ± 1% of brain acetylcholinesterase. This promising result opens the possibility to use marketed positively charged oximes in medical countermeasures against organophosphorus poisoning for reactivation of central acetylcholinesterase by implementing a non-invasive approach, via the “nose-brain” pathway.

AB - New mixed cationic liposomes based on L-α-phosphatidylcholine and dihexadecylmethylhydroxyethylammonium bromide (DHDHAB) were designed to overcome the BBB crossing by using the intranasal route. Synthesis and self-assembly of DHDHAB were performed. A low critical association concentration (0.01 mM), good solubilization properties toward hydrophobic dye Orange OT and antimicrobial activity against gram-positive bacteria Staphylococcus aureus (MIC=7.8 μg mL–1) and Bacillus cereus (MIC=7.8 μg mL–1), low hemolytic activities against human red blood cells (less than 10%) were achieved. Conditions for preparation of cationic vesicles and mixed liposomes with excellent colloidal stability at room temperature were determined. The intranasal administration of rhodamine B-loaded cationic liposomes was shown to increase bioavailability into the brain in comparison to the intravenous injection. The cholinesterase reactivator, 2-PAM, was used as model drug for the loading in cationic liposomes. 2-PAM-loaded cationic liposomes displayed high encapsulation efficiency (∼ 90%) and hydrodynamic diameter close to 100 nm. Intranasally administered 2-PAM-loaded cationic liposomes were effective against paraoxon-induced acetylcholinesterase inhibition in the brain. 2-PAM−loaded liposomes reactivated 12 ± 1% of brain acetylcholinesterase. This promising result opens the possibility to use marketed positively charged oximes in medical countermeasures against organophosphorus poisoning for reactivation of central acetylcholinesterase by implementing a non-invasive approach, via the “nose-brain” pathway.

KW - Acetylcholinesterase

KW - Cationic liposomes

KW - Drug delivery systems

KW - Organophosphorus agent

KW - Paraoxon

KW - Pralidoxime chloride

KW - Self-assembly

KW - Surfactant

UR - http://www.scopus.com/inward/record.url?scp=85050484821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050484821&partnerID=8YFLogxK

U2 - 10.1016/j.colsurfb.2018.07.049

DO - 10.1016/j.colsurfb.2018.07.049

M3 - Article

C2 - 30059851

AN - SCOPUS:85050484821

VL - 171

SP - 358

EP - 367

JO - Colloids and Surfaces B: Biointerfaces

JF - Colloids and Surfaces B: Biointerfaces

SN - 0927-7765

ER -